Abstract
Scalp hair loss is an underreported adverse event of somatostatin analogs therapy that in severe cases may require treatment withdrawal. It can be related to an acute decrease in GH / IGF ‐1 levels, but a direct effect cannot be ruled out.
Cite
CITATION STYLE
APA
Alvarez‐Escola, C., Cárdenas‐Salas, J. J., Pelegrina, B., Sanz‐Valtierra, A., & Lecumberri, B. (2015). Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery. Clinical Case Reports, 3(11), 945–948. https://doi.org/10.1002/ccr3.388
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free